Investment Banking

Lazard lands lead role on $11bn Sanofi takeover

French healthcare group's takeover of a US haemophilia treatment firm is the third-biggest M&A deal of 2018

Lazard lands lead role on $11bn Sanofi takeover
Photo: Getty Images

Lazard is advising French healthcare group Sanofi on the third-biggest M&A deal announced this year — another early win for Europe's independent investment banks on large-scale transactions in 2018.

Sanofi will pay $11.6bn for US haemophilia treatment specialist Bioverativ, which was spun off by Massachusetts biotech firm Biogen in February 2017.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump